Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

The goal of this clinical trial is to compare the safety and efficacy of sequential Transarterial Chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) versus Y90-radioembolisation (SIRT), followed by systemic therapy in patients with large, locally advanced, unresectable Hepatocellular carcinoma (HCC). The main question it aims to answer is whether Sequential TACE-SBRT potentially gives longer Progression-free survival (PFS) benefit with similar toxicities as compared with Y90 SIRT. Participants will be recruited via multidisciplinary meetings (MDTs) with hepatobiliary sur

Trial Details

NCT ID
NCT07293468
Phase
PHASE2 / PHASE3
Sponsor
Tuen Mun Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Transarterial chemoembolization (TACE)
  • Stereotactic Body Radiation Therapy (SBRT)
  • SIRT Yttrium-90
  • Atezolizumab & Bevacizumab
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • Patients diagnosed with HCC either by histology or by the American Association for the Study of Liver Diseases Criteria (AASLD) 2018
  • Patients age 18-80 years of age with HCCs deemed unresectable at the Multidisciplinary Team Meetings (MDTs) because of the following:
  • R0 resection not feasible e.g. unfavourable tumour location
  • Remnant liver volume \<30% in non-cirrhotic patients or 40% in cirrhotic patients

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →